Nucleotide Excision Repair and Transcriptional Regulation: TFIIH and Beyond.
Transcription factor IIH (TFIIH) is a multiprotein complex involved in both transcription and DNA repair, revealing a striking functional link between these two processes. Some of its subunits also belong to complexes involved in other cellular processes, such as chromosome segregation and cell cycle regulation, emphasizing the multitasking capabilities of this factor. This review aims to depict the structure of TFIIH and to dissect the roles of its subunits in different cellular mechanisms. Our understanding of the biochemistry of TFIIH has greatly benefited from studies focused on diseases related to TFIIH mutations. We address the etiology of these disorders and underline the fact that TFIIH can be considered a promising target for therapeutic strategies.
Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique/Institut National de la Santé et de la Recherche Médicale/Université de Strasbourg, 67404 Illkirch Cedex, Commune Urbaine Strasbourg, France; email: compe@igbmc.fr , egly@igbmc.fr.
Emmanuel
E
Compe
Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique/Institut National de la Santé et de la Recherche Médicale/Université de Strasbourg, 67404 Illkirch Cedex, Commune Urbaine Strasbourg, France; email: compe@igbmc.fr , egly@igbmc.fr.
Jean-Marc
JM
Egly
D002453:Cell Cycle / Q000187:drug effects / Q000235:genetics; D018797:Cell Cycle Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D020090:Chromosome Segregation; D004247:DNA / Q000235:genetics / Q000378:metabolism; D004249:DNA Damage; D004260:DNA Repair / Q000187:drug effects*; D006801:Humans; D008958:Models, Molecular; D058990:Molecular Targeted Therapy; D009154:Mutation; D010655:Phenylenediamines / Q000627:therapeutic use; D021122:Protein Subunits / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D011743:Pyrimidines / Q000627:therapeutic use; D013148:Spironolactone / Q000627:therapeutic use; D051758:Transcription Factor TFIIH / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism; D014158:Transcription, Genetic / Q000187:drug effects*; D054463:Trichothiodystrophy Syndromes / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D014983:Xeroderma Pigmentosum / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism / Q000473:pathology
D018797:Cell Cycle Proteins; D010655:Phenylenediamines; D021122:Protein Subunits; D011743:Pyrimidines; C000596184:THZ1 compound; D051758:Transcription Factor TFIIH; D013148:Spironolactone; D004247:DNA
DNA repair; TFIIH; cell cycle; human diseases; transcription